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ABSTRACT 
Objective: To study the prevalence of ADRs associated with the use of anti-tubercular drugs in patients with tuberculosis in a tertiary care hospital.  
Methods: A prospective observational and active surveillance study was conducted in the department of pulmonology and DOTS Centre in Owaisi 
Hospital and Research Centre over a period of 6 mo after the study was approved by IRB. The patients who gave informed consent were included in 
the study and their information was analysed after being recorded in a data collection form.  
Results: Descriptive statistical analysis was carried out to generate results, the continuous measurement being presented as mean standard 
deviation (min-max) and categorical measurement presented in number (%). The results showed the prevalence of ADRs to be 69%. The prevalence 
of ADRs was more in females (55%) than in males (45%) and 75.9% of them reporting more than 1 ADR. ADR’s affecting the skin and appendages 
were high (23.56%) while ADR’s affecting gastrointestinal system (19.28%), the hepatic system (4.28%), the musculoskeletal system (15.7%), 
Central and peripheral nervous system (7.85%), Vision (0.7%) were comparatively less.  
Conclusion: The study highlighted the importance of developing strategies to ameliorate ADRs both to improve the quality of patient care and to 
control TB safely.  
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Infectious diseases are the important leading causes of death (morbidity 
and mortality) among the people of Tuberculosis (TB), HIV/AIDS and 
with other chronic diseases [1]. Among various infectious diseases, TB is 
one of the leading contagious infection responsible for death which is 
affected by Mycobacterium tuberculosis [2]. 
In 1993, WHO declared TB as a global emergency and National 
Tuberculosis Programmes (NTPs) strategy was started all over the 
world to employ the daily regimens/Directly Observed Treatment-
Short course (DOTS) of anti-TB drugs [3]. 
The long duration of TB treatment drugs like Isoniazid, 
Pyrazinamide, Rifampin, Ethambutol and Streptomycin–are 
potentially responsible to cause adverse drug reactions like 
hepatotoxicity, visual disturbance, arthralgia, headache, skin rashes 
etc. These Adverse reactions mostly observed/occur in the first 
three months of treatment. A large number of patients are exposed 
to anti-TB drugs at PHCs of RNTCP/DOTS, yet no such major 
findings were observed in monitoring/detecting of ADRs. The ADRs 
are one of the major reasons for patient default about their 
treatment [4]. 
The high prevalence of TB treatment highlight the need of the 
importance of the clinical pharmacist, for monitoring ADRs and to 
increase awareness of ADRs among the patients and health care 
professionals by reporting any suspected ADRs. This type of activity 
of the pharmacist will help in minimizing ADRs [5, 6]. 
The present study was conducted to evaluate the prevalence of 
adverse drug reactions in patients suffering from tuberculosis. As TB 
is a widespread disease in major parts of India several steps have 
been taken to eradicate the disease and programs such as RNTCP 
and DOTS were initiated. The occurrence of ADRs is one of the main 
reasons of non-compliance, by designing a prospective 
observational study we have targeted the TB affected patients. This 
study also gives us an idea on all the common ADRs that occur 
during the course of treatment intending to provide knowledge 
about the ADRs associated with anti-tubercular drugs. 
A hospital based prospective observational study was conducted over a 
period of 6 mo (August 2014-February 2015) in Out Patient Department 
of Owaisi Hospital and Research Centre, Hyderabad, Telangana State, 
India after it was approved by Institutional Ethics Committee (IEC). 
Patients of both genders willing to give verbal informed consent and 
above the age of 17, patients with family history of tuberculosis, 
patients on DOTS therapy and patients diagnosed with TB were 
included for the study whereas pregnant women, patients who were 
not willing to give verbal informed consent, in-patients or the 
hospitalized patients and patients who were not able to communicate 
or have a language problem were excluded for the study. 
120 patients met the inclusion criteria and so were enrolled for the 
study after obtaining Informed consent either from patients or 
through a legally acceptable representative for documentation of 
any suspected ADRs.  
The relevant details such as clinical presentation, date of starting 
and stopping of event, relevant laboratory investigations, other 
relevant history including pre-existing diseases, suspected 
medication (including dose, frequency, route of administration, 
dates and duration of administration and indications for use) and 
concomitant medicines (including self-medication and herbal 
remedies) of inpatients were recorded on a patient data collection 
form along with demographic details such as age, gender, weight, 
diagnosis and prescription details like date, DOTS therapy (Category 
I and Category II) given to the patient, duration of treatment. 
Adverse drug reactions related to anti-tubercular medications were 
listed out using Medscape and other related articles and journals. 
The adverse drug reaction caused by the individual drug was noted 
in the data collection form than were detected and brought to the 
notice of the medical officer for further evaluation. Details regarding 
the suspected drug, date of suspected drug started, date of onset of 
the reaction, a brief description of the reaction were documented 
and authenticated by the signature of the in charge medical officers 
and date of reporting. 
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The data analysis was done using Statistical Methods such as 
Descriptive statistical analysis using MS excel spreadsheet to 
generate graphs, tables etc., and results on continuous measurement 
were presented on mean standard deviation (min-max) and results 
on categorical measurement were presented in number (%) and 
were tabulated as follows:  
Out of 120 patients enrolled in the study a total of 140 ADRs were 
reported by 83(69.16%) patients and 37 (30.84%) patients did not 
report any ADR. 
The prevalence of ADRs in males and females was 45% and 55% 
respectively depicted in table 1 
The patients who received Isoniazid, Rifampicin, Pyrazinamide and 
ethambutol were found with more number of ADRs i.e., 40 (75.5%) 
when compare with other combinations. ADRs were divided into 2 
groups-single ADR and more than 1 ADR table 2 
The percentage of patients with single and more than 1 ADR was 
24.09% and 75.9% respectively. 
  
Table 1: Demographic data (Gender) 
Gender No. of patients % of patients 
Male 54 45 
Female 66 55 
Total 120 100 
 
Table 2: Adverse drug reactions 
Adverse drug reactions No. of patients % of patients 
Single adr 20 24.09 
More than 1 adr 63 75.9 
Total adr 83 99.99 
The common adverse drug reactions related to individual drugs are shown in table 3 
 
Table 3: Details on distribution of types of ADRs 
ADR No. of ADRs % of ADRs 
RIFAMPICIN   
Rash 10  7.14 
hepatotoxicity  6   4.28 
Orange urine 30  21.4 
ISONIAZID   
Rash 23  16.42 
Nausea & vomiting 11  7.85 
Peripheral neuropathy 7.1 10  







Joint pain 20   14.2 
Hyperuricemia 2  1.42 
ETHAMBUTOL   
Anorexia 5  3.57 
Stomach cramps 5  3.57 
Headache 5  3.57 
Optic neuritis 1  0.7 
ADR’s affecting the Skin and appendages were high, i.e., 33(23.56%), while ADR’s affecting other systems were as follows gastrointestinal system 27 
(19.28), i.e., hepatic system, i.e., 6 (4.28) musculoskeletal system, i.e., 22(15.7), central and peripheral nervous system, i.e., 15 (7.85)., Vision i.e., 1 
(0.7). the most common adverse effect caused by rifampicin was orange colored urine, i.e., 30 (21.4%).  
 
The common adverse drug reactions of Rifampicin were found to be 
orange colour urine 36% (n=30), hepatotoxicity 8% (n=6), and rash 
around 12% (n=10). 
The common adverse drug reactions of Isoniazid were found to be 
rash and generalised itching 28% (n=23), nausea and vomiting 13% 
(n=11), peripheral neuropathy 12% (n=10) and loss of appetite 8% 
(n=6). 
The common adverse drug reactions of Pyrazinamide were found to 
be joint pains 24% (n=20), anaemia 8% (n=6), hyperuricemia 3% 
(n=2). 
The common adverse drug reactions of Ethambutol were found to be 
anorexia 12 % (n=10), stomach cramps 8% (n=6), headache 6% 
(n=5), and optic neuritis 2% (n=1). 
However in our study it was found that the prevalence of TB was 
more in females than in males and most of the patients reported 
orange colour urine and the prevalence of Tuberculosis is more in 
females by 10% than in males(The percentage of females affected with 
tuberculosis is 55% and the percentage of males affected is 45%.) 
Orange coloured urine was reported by most of the patients which 
was caused by rifampicin followed by rash and generalised itching 
caused by isoniazid. 
The study showed that the prevalence of ADRs with anti-tubercular 
drugs was 69.16%. These ADRs had a substantial impact on TB 
control. Majority of the patients felt that after taking their treatment 
the condition worsened which was merely due to ADR of anti-
tubercular therapy (ATT), which shows wrong conception about 
treatment. It was minimized by interviewing and patient counseling. 
Our study concludes that there is a need of a close monitoring 
system for proper detection of ADRs caused by anti-TB drugs. 
Counselling of patients for timely prevention, detection and 
management of ADRs will help in minimising the further occurrence 
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of ADR. Our study highlighted the importance of developing 
strategies to ameliorate ADRs both to improve the quality of patient 
care and to control TB safely. 
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